Altropane (Boston Life Science).
Boston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and attention deficit hyperactivity disorder (ADHD) [329661]. Altropane is currently in phase III clinical trials for PD and phase II clinical trials for ADHD.
Cattabeni
Flaminio
F
Department of Pharmacological Sciences, Centre of Neuropharmacology, University of Milan, via Balzaretti 9, 20133, Milano, Italy. flaminio.cattabeni@unimi.it
D000818:Animals; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003042:Cocaine / Q000031:analogs & derivatives*; D006801:Humans; D010300:Parkinson Disease / Q000175:diagnosis; D019275:Radiopharmaceuticals; D013678:Technology, Pharmaceutical / Q000379:methods; D014055:Tomography, Emission-Computed / Q000379:methods; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods
C102282:N-iodoallyl-2-carbomethoxy-3-(4-fluorophenyl)tropane; D019275:Radiopharmaceuticals; D003042:Cocaine